Targeted Deprescribing in Patients on Hemodialysis

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 5, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how to reduce the number of unnecessary medications taken by patients on hemodialysis (HD), a treatment for those with end-stage kidney disease. HD patients typically take around 19 medications each day, and research shows that many of these medications may not be suitable for them. The goal of the study is to test new tools that can help doctors identify and stop the use of nine specific medications that are often prescribed but may not be effective or safe for HD patients. By doing this, the researchers hope to lower the number of medications patients take and improve their overall health.

To participate in this trial, individuals must be at least 18 years old, have been receiving outpatient hemodialysis treatment for at least three months, and be able to read and understand English to give their consent. Participants can expect to help improve medication practices at HD centers across Canada, which may lead to better health outcomes and fewer side effects from medications. This trial is currently recruiting participants and aims to make significant changes in how medications are prescribed to HD patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18+ years
• • Have been receiving outpatient HD treatment at one of the four study sites for at least the past three months
• • Able to read and understand English and provide consent
• Exclusion Criteria:
• • - Acute starts to HD